Magnetically actuated nanoantennas for wireless glioblastoma therapy.
Overview
Abstract
Glioblastoma (GBM) remains a formidable clinical challenge, characterized by invasive growth, therapeutic resistance, and dismal patient survival. We report the development of HITMAN (highly localized electric field–induced tumor therapy using magnetically actuated nanoantennas), a wireless bioelectric therapy that selectively eradicates GBM cells with cellular precision. Magnetically actuated nanoantennas convert low-frequency (≤200 kHz), deep-brain–penetrant magnetic fields into localized electric fields, thereby triggering protein unfolding, membrane disruption, and ER stress. In vitro, HITMAN demonstrated superior efficacy compared to temozolomide (TMZ), significantly decreasing viability in drug-resistant, patient-derived GBM cells by 52.2%, versus 10% with TMZ while sparing neurons and astrocytes. Mechanistically, HITMAN activated the unfolded protein response and autophagy pathways, suppressed cell cycle and adhesion genes, reduced Ki-67 expression, disrupted cytoskeletal architecture, and elevated p53 levels, underscoring a multifaceted antitumor mechanism. In orthotopic mouse models, HITMAN significantly inhibited tumor growth, extended median survival by more than 50%, and exhibited no systemic toxicity. Thus, HITMAN offers a minimally invasive, spatially precise, and clinically translatable therapy for GBM.
Reproduced under the paper's license (CC BY-NC), from the paper cited above.
Code
The paper links to its data, not to its authors' code: see the Data section.
The paper's code and data availability statement is in the Data section.
Tracing map
A tracing map links a paper to the code its authors published: this paper has none, so it has no map.
Data
Datasets cited
- geo:GSE324656, at NCBI GEO; found in “Data, code, and materials availability:”
Data, code, and materials availability
All data needed to evaluate the conclusions in the paper are present in the paper and/
Reproduced under the paper's license (CC BY-NC), from the paper cited above.
Versions
The history of this record: each version stored by the harvester or made by a correction of its authors or of the maintainers of its code, and what changed in its facts. The texts of the paper (its abstract, its availability statements) are not part of it; versions that changed only those are not listed.
Version 1, 27 September 2026: the first record
Recorded: type, language, journal, volume, issue, pages, dates, 10 authors, 9 MeSH terms, 2 funders, 90 references.
Cite
This paper
Saha, M., Khan, I. N., Joy, B., Chen, S.-Y., Yang, H.-T., Patel, P., Jang, K., Zhang, P., Azeemi, F., & Sarkar, D. (2026). Magnetically actuated nanoantennas for wireless glioblastoma therapy. Science advances, 12(37), eaeb1237. https://
BibTeX
@article{saha2026magneti
author = {Saha, Monochura and Khan, Ishaq N and Joy, Baju and Chen, Shun-Ying and Yang, Hao-Tung and Patel, Preet and Jang, Kyuho and Zhang, Pengrui and Azeemi, Faheem and Sarkar, Deblina},
title = {{Magnetically actuated nanoantennas for wireless glioblastoma therapy}},
journal = {Science advances},
year = {2026},
month = sep,
volume = {12},
number = {37},
pages = {eaeb1237},
publisher = {American Association for the Advancement of Science},
issn = {2375-2548},
doi = {10.1126/
url = {https://
pmid = {42715333},
pmcid = {PMC13557086}
}
RIS
TY - JOUR
AU - Saha, Monochura
AU - Khan, Ishaq N
AU - Joy, Baju
AU - Chen, Shun-Ying
AU - Yang, Hao-Tung
AU - Patel, Preet
AU - Jang, Kyuho
AU - Zhang, Pengrui
AU - Azeemi, Faheem
AU - Sarkar, Deblina
TI - Magnetically actuated nanoantennas for wireless glioblastoma therapy
T2 - Science advances
J2 - Sci Adv
PY - 2026
DA - 2026/
VL - 12
IS - 37
SP - eaeb1237
SN - 2375-2548
PB - American Association for the Advancement of Science
DO - 10.1126/
UR - https://
LA - en
ER -
CSL-JSON
{
"id": "10.1126/
"type": "article-journal",
"title": "Magnetically actuated nanoantennas for wireless glioblastoma therapy",
"container-title": "Science advances",
"author": [
{
"family": "Saha",
"given": "Monochura"
},
{
"family": "Khan",
"given": "Ishaq N"
},
{
"family": "Joy",
"given": "Baju"
},
{
"family": "Chen",
"given": "Shun-Ying"
},
{
"family": "Yang",
"given": "Hao-Tung"
},
{
"family": "Patel",
"given": "Preet"
},
{
"family": "Jang",
"given": "Kyuho"
},
{
"family": "Zhang",
"given": "Pengrui"
},
{
"family": "Azeemi",
"given": "Faheem"
},
{
"family": "Sarkar",
"given": "Deblina"
}
],
"container-title-short":
"volume": "12",
"issue": "37",
"page": "eaeb1237",
"DOI": "10.1126/
"PMID": "42715333",
"PMCID": "PMC13557086",
"ISSN": "2375-2548",
"publisher": "American Association for the Advancement of Science",
"URL": "https://
"language": "en",
"issued": {
"date-parts": [
[
2026,
9,
9
]
]
}
}
Similar papers
The papers with a page that share the most with this one: the tools found in their code, their categories, datasets, cited references and authors, the rarest counting most.
- [1] doi:10.1016/j.xcrm.2026.102850 [code]
- Patient-derived organoids predict personalized drug response and reveal alternative therapeutic options in glioblastoma.Journal: Cell reports. MedicineIn common: clinical / translational, other condition, mouse, 3 references
- [2] doi:10.1038/s41467-026-76587-0 [code]
- Uncovering the signaling networks of disseminated glioblastoma cells in vivo with INSIGHT.Journal: Nature communicationsIn common: other condition, mouse, 3 references
- [3] doi:10.1038/s41467-026-71021-x
- Developing a multimodal therapy for glioblastoma using oncolytic virus delivering CD19 and EGFRvIII antigens and bi-specific CARs.Journal: Nature communicationsIn common: other condition, mouse, 3 references
- [4] doi:10.1002/advs.75097 [code]
- Remote Magnetomechanical Neuromodulation Uncovers Therapeutic Mechanisms for Alleviating Parkinsonian Symptoms in Freely Moving Mice.Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)In common: clinical / translational, mouse, 2 references
- [5] doi:10.3389/fcell.2026.1812038
- Human pluripotent stem cell-derived neuroepithelial cells develop into an organizer for optic tectum formation in the chicken diencephalon.Journal: Frontiers in cell and developmental biologyIn common: 4 references
- [6] doi:10.1080/19336896.2026.2710965
- Epigenetic changes associated with the progression of prion disease in Syrian hamsters (&
lt;i& gt;Mesocricetus auratus& lt;/ i& gt;). Journal: PrionIn common: other condition, 4 references - [7] doi:10.1080/10717544.2026.2660007
- Angiopep-2-decorated bacterial outer membrane vesicles penetrate the blood-brain barrier for glioblastoma chemo-immunotherapy.Journal: Drug deliveryIn common: other condition, mouse, 2 references
- [8] doi:10.1158/2767-9764.crc-25-0579 [code]
- Glioblastoma Subtypes Exhibit Distinct Migration Mechanics and Immune Responses.Journal: Cancer research communicationsIn common: other condition, mouse, 2 references
- [9] doi:10.3389/fphys.2026.1844142
- CRISPR/
Cas9-mediated & lt;i& gt;PHOX2B& lt;/ i& gt; functional knock-out in IMR32 neuroblastoma cells impairs neuronal excitability through dysregulation of ion channels genes. Journal: Frontiers in physiologyIn common: other condition, 3 references - [10] doi:10.1016/j.stemcr.2026.103012
- Identification of novel genes with enriched expression in human intermediate progenitors reveals a key role for CDKN3 in cortical development.Journal: Stem cell reportsIn common: mouse, 3 references
Contribute
The authors of this paper can claim it, correct its record and validate its tracing map, and the maintainers of its code (its owner, or a public member of its organization) correct what it says of their repository; anyone signed in can ask for its removal. Every request goes to OSCR's own machine, which answers it; your account page follows them.
Sign in with ORCID to claim this paper as one of its authors, correct its record or validate its tracing map: when the paper's metadata lists your ORCID iD, you are recognized at once. Maintainers of its code: sign in with GitHub, then claim the repository on your account page.
Claim this paper
Correct its record
Say what each link of this record is, remove the ones that are not the paper's, add the ones that are missing. The correction becomes a new version of the record, in its Versions section.
Request its removal
To ask OSCR to remove this record, the copies of its authors' scripts or its tracing map, use the removal request page: signed in, you say who you are, what to remove and why, then review and confirm the request. Published rules decide every request (how).
Discussion, reproductions, activity
Discussion: questions and error reports about this paper and its code, from signed-in readers and its authors. It opens with sign-in.
Reproductions: reports from readers who ran the authors' code: what they reproduced, with which environment, commit and data. It opens with sign-in.
Activity: what happens around this paper: new versions of its record, its map's validation, discussions and reproductions. It opens with sign-in.